ClinicalTrials.gg
Not yet recruitingNCT07905599MERITUpdated Oct 29, 2026

Molecular Evidence of Rejection Intervention Trial

An interventional study of Prednisone and Placebo in Heart Transplant Rejection, sponsored by CareDx. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by CareDx · Not applicable, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

MERIT is a double-blind, multi-center, placebo-controlled, randomized clinical trial. Heart transplant recipients with dual-positive GEP/dd-cfDNA assays with a corresponding negative biopsy between 2 months and 2 years post-transplant will be randomized to treatment with either high-dose oral steroids or placebo, in addition to standard of care therapy.

Read the detailed description

This study is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial enrolling approximately 200 adult heart transplant recipients across up to 20 transplant centers in the United States and Canada. Eligible participants are adults (≥18 years) between 2 months and 2 years post-heart transplant who have simultaneous dual-positive molecular testing-defined as both an elevated gene expression profiling (GEP) and elevated donor derived cell-free DNA (dd-cfDNA) result-paired with an endomyocardial biopsy showing no evidence of acute rejection (ISHLT grade 0R or 1R and pAMR0).

Participants will be randomized in a 1:1 ratio to receive either high-dose oral prednisone (100 mg daily for 3 consecutive days) or matched placebo, in addition to standard of care therapy. Treatment assignment will be blinded to participants, investigators, and study personnel.

The primary objective is to determine whether high-dose steroid therapy improves clinical outcomes at 180 days following randomization.

Participants will be followed for 12 months after randomization, with scheduled assessments at 28 days, 180 days, and 365 days, including clinical evaluation, laboratory testing, echocardiography, and molecular biomarker measurements.

By evaluating whether early intervention based on molecular evidence of graft injury can improve outcomes, this study aims to inform clinical decision-making and potentially establish a new treatment paradigm for heart transplant recipients with molecular evidence of allograft injury that is not detected by biopsy.

02

Conditions studied

  • Heart Transplant Rejection
03

In context

Lead sponsor

CareDx is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has provided
  2. Age ≥18 years old at the time of consent
  3. Heart transplant recipient between 2 months to 2 years post-transplant
  4. Simultaneous dual-positive GEP/dd-cfDNA result, defined as both a dd-cfDNA level ≥0.20% AND one of the following:

    1. a GEP score ≥30 (if 55-180 days post-transplant)
    2. a GEP score ≥34 (if ≥181 days post-transplant)
  5. An endomyocardial (EMB) showing no rejection [(0R or 1R) and pAMR0] AND both of the following:

    1. Performed on the same day or up to 10 calendar days after the simultaneous dual-positive GEP/dd-cfDNA draw.
    2. No intention to treat the subject empirically for ACR or AMR based on other clinical features, including DSA
  6. If the closest GEP/dd-cfDNA result prior to screening was also dual positive, both of the following must be true:

    1. GEP score OR dd-cfDNA level has increased from previous value
    2. Neither GEP score nor dd-cfDNA level have decreased from previous value
  7. Randomization within 14 calendar days of the simultaneous dual positive GEP/dd-cfDNA draw
  8. All patients of must have a negative pregnancy test prior to randomization. Use of must be followed per site standard clinical protocol.
  9. Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Multiorgan or bone marrow transplant recipient
  2. On an organ transplant waitlist at the time of screening
  3. In-patient at the time of study screening
  4. Presence of an active infection being treated with an antibiotic, antifungal, and/or antiviral or
  5. Random capillary blood glucose of >180 mg/dL on day of enrollment
  6. Enrollment in another interventional study or exposed to experimental drug in the last 30 days
  7. \<55% on the most recent echocardiogram
  8. Most recent EMB before screening showing ACR (≥2R) and/or AMR (≥pAMR1)
  9. Intent to transfer heart transplant care to another center in the 12-months after randomization
  10. Patient who, in the opinion of the treating provider or Investigator, is not an appropriate candidate for study participation due to safety concerns, medical judgment, or other clinical considerations.
  11. Patient receiving at a dose equivalent to ≥25 mg/day
  12. Clinical or hemodynamic concern for rejection-related heart failure, as determined by the treating clinician
  13. Patient receiving granulocyte colony stimulating factor (GCSF) within the past 30 days
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    High Dose Prednisone

    Three days, 100mg of prednisone

    Drug: Prednisone

  • Placebo comparator
    Placebo

    Matched placebo

    Drug: Placebo

Interventions

  • 100mg per day for three days following randomization

  • DrugPlacebo

    Matched placebo in same patient population.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.

    Time frame: Assessed at 180 (± 14) days post-randomization

Secondary outcomes

  1. Secondary Endpoint

    A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.

    Time frame: Assessed at 28 (±7) days post-randomization

  2. Safety Endpoint

    Incidence of infection requiring treatment with antibiotics, antivirals, and/or antifungals, hyperglycemia requiring an unplanned clinic visit, emergency room visit or hospitalization, and bone fracture or avascular necrosis.

    Time frame: Randomization through study completion, an average of 1 year.

Other outcomes

  1. 6 Month Exploratory Endpoint

    Evaluate additional biomarkers including DSA and Teno torque virus (TTV) levels; presence of ≥1 de novo DSA.

    Time frame: Assessed at 180 (± 14) days post-randomization

  2. 12 Month Exploratory Endpoint

    A hierarchical composite outcome of time to death or re-transplantation, time to graft dysfunction (LVEF \<50%), time to ACR 2R higher and/or pAMR1 or higher, hospitalization (yes/no), dd-cfDNA \<0.20% (yes/no), and percent reduction in dd-cfDNA from randomization.

    Time frame: Assessed at 365 (±30) days post-randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gregson J, Taylor D, Owen R, Collier T, J Cohen D, Pocock S. Hierarchical Composite Outcomes and Win Ratio Methods in Cardiovascular Trials: A Review and Consequent Guidance. Circulation. 2025 Jun 3;151(22):1606-1619. doi: 10.1161/CIRCULATIONAHA.124.070251. Epub 2025 Jun 2. PubMed 40455842 ↗
  • Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6. PubMed 21900289 ↗
  • Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):914-56. doi: 10.1016/j.healun.2010.05.034. No abstract available. PubMed 20643330 ↗
  • Teuteberg J, Patel S, Baran DA, Shah P, Sayer G, Nguyen AB, Ravichandran A, Hall S, Pinney S, DePasquale E, Raval N, Kobulnik J, Fan CS, Oreschak K, Wang S, Khush KK, Uriel N. Multimodal molecular testing provides prognostic value for heart transplant recipients. J Heart Lung Transplant. 2026 Mar;45(3):388-400. doi: 10.1016/j.healun.2025.11.013. Epub 2025 Nov 24. PubMed 41297735 ↗
  • Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczynski M, Fiocchi R, Hoefer D, Deng M, Leprince P, Hiller D, Eubank L, Deljkich E, Yee JP, Vanhaecke J. Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients. BMC Cardiovasc Disord. 2015 Oct 9;15:120. doi: 10.1186/s12872-015-0106-1. PubMed 26452346 ↗
  • Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Shahzad K, Hiller D, Yee J, Valantine HA; IMAGE Study Group. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation. 2014 Mar 27;97(6):708-14. doi: 10.1097/01.TP.0000443897.29951.cf. PubMed 24637869 ↗
  • Mehta A, Goldberg J, Bagchi P, Marboe C, Shah KB, Najjar SS, Hsu S, Rodrigo ME, Jang MK, Cochrane A, Tchoukina IF, Kong H, Lohmar BJ, Mcnair E, Valantine HA, Agbor-Enoh S, Berry GJ, Shah P. Pathologist interrater reliability and clinical implications of elevated donor-derived cell-free DNA beyond heart transplant rejection, on behalf of the GRAfT investigators. J Heart Lung Transplant. 2025 May;44(5):803-812. doi: 10.1016/j.healun.2024.10.006. Epub 2024 Oct 17. PubMed 39424014 ↗
  • Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczynski M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 2016 Sep 1;37(33):2591-601. doi: 10.1093/eurheartj/ehv682. Epub 2016 Jan 7. PubMed 26746629 ↗
  • Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran DA, Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. J Heart Lung Transplant. 2024 Sep;43(9):1409-1421. doi: 10.1016/j.healun.2024.05.003. Epub 2024 May 15. PubMed 38759766 ↗
  • Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, Ewald G, Berman P, Kanwar M, Hiller D, Yee JP, Woodward RN, Hall S, Kobashigawa J. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. Am J Transplant. 2019 Oct;19(10):2889-2899. doi: 10.1111/ajt.15339. Epub 2019 Apr 8. PubMed 30835940 ↗
  • Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL, Starling RC, Murali S, Pauly DF, Baron H, Wohlgemuth JG, Woodward RN, Klingler TM, Walther D, Lal PG, Rosenberg S, Hunt S; CARGO Investigators. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006 Jan;6(1):150-60. doi: 10.1111/j.1600-6143.2005.01175.x. PubMed 16433769 ↗
  • Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, Farrero M, Garcia-Guereta L, Jamero G, Khush K, Lavee J, Pouch S, Patel J, Michaud CJ, Shullo MA, Schubert S, Angelini A, Carlos L, Mirabet S, Patel J, Pham M, Urschel S, Kim KH, Miyamoto S, Chih S, Daly K, Grossi P, Jennings DL, Kim IC, Lim HS, Miller T, Potena L, Velleca A, Eisen H, Bellumkonda L, Danziger-Isakov L, Dobbels F, Harkess M, Kim D, Lyster H, Peled Y, Reinhardt Z. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023 May;42(5):e1-e141. doi: 10.1016/j.healun.2022.10.015. Epub 2022 Dec 20. No abstract available. PubMed 37080658 ↗
  • Singh TP, Hsich E, Cherikh WS, Perch M, Hayes D Jr, Lewis A, Dellgren G, Cogswell R; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation. J Heart Lung Transplant. 2025 Dec;44(12):1857-1873. doi: 10.1016/j.healun.2025.04.014. Epub 2025 Apr 27. No abstract available. PubMed 40300677 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Dec 2028, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Oct 29, 2026
StartEst.
Mar 2027
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07905599
Lead sponsor
CareDx
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Mar 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Elizabeth Kennedy
Contact
ekennedy@caredx.com
(415) 287-2300 ext. 5929
Srey Yin
Contact
syin@caredx.com
Kiran Khush, MD
principal investigator · Stanford University
Nir Uriel, MD, MSc, FACC
principal investigator · Columbia University Irving Medical Center, Weill Cornell Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion